Pharmacological therapy is only part of the answer to improving mental health
Summary of the issues surrounding psychotropic drug use in residential aged care facilities (RACFs)
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Hilmer SN, Gnjidic D. Rethinking psychotropics in nursing homes. Med J Aust 2013; 198: 77. <MJA full text>
- 2. Snowdon J. Mental health service delivery in long-term care homes. Int Psychogeriatr 2010; 22: 1063-1071.
- 3. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr 2010; 22: 1025-1039.
- 4. Conn DK, Seitz DP. Advances in the treatment of psychiatric disorders in long-term care homes. Curr Opin Psychiatry 2010; 23: 516-521.
- 5. Popp J, Arlt S. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimers disease. Curr Opin Psychiatry 2011; 24: 556-561.
- 6. de Rooij AHPM, Luijkx KG, Declercq AG, Schols JM. Quality of life of residents with dementia in long-term care settings in the Netherlands and Belgium: design of a longitudinal comparative study in traditional nursing homes and small-scale living facilities. BMC Geriatr 2011; 11: 20.
- 7. Brownie S, Nancarrow S. Effects of person-centered care on residents and staff in aged-care facilities: a systematic review. Clin Interv Aging 2013; 8: 1-10.
- 8. Comondore VR, Devereaux PJ, Zhou Q, et al. Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. BMJ 2009; 339: b2732.
- 9. Macfarlane S, McKay R, Looi JC. Limited antidepressant efficacy in depression in dementia, in the context of limited evidence. Aust N Z J Psychiatry 2012; 46: 595-597.
- 10. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; (2): CD008191.
- 11. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD003476.
- 12. Bergh S, Selbæk G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ 2012; 344: e1566.
- 13. O’Halloran J, Britt H, Valenti L. General practitioner consultations at residential aged-care facilities. Med J Aust 2007; 187: 88-91. <MJA full text>
- 14. Gadzhanova S, Reed R. Medical services provided by general practitioners in residential aged-care facilities in Australia. Med J Aust 2007; 187: 92-94. <MJA full text>
- 15. McSweeney K, Jeffreys A, Griffith J, et al. Specialist mental health consultation for depression in Australian aged care residents with dementia: a cluster randomized trial. Int J Geriatr Psychiatry 2012; 27: 1163-1171.
- 16. Jones TS, Matias M, Powell J, et al. Who cares for older people with mental illness? A survey of residential aged care facilities in the Australian Capital Territory: implications for mental health nursing. Int J Ment Health Nurs 2007; 16: 327-337.
- 17. Beer C, Lowry R, Horner B, et al. Development and evaluation of an educational intervention for general practitioners and staff caring for people with dementia living in residential facilities. Int Psychogeriatr 2011; 23: 221-229.
- 18. Rosemond CA, Hanson LC, Ennett ST, et al. Implementing person-centered care in nursing homes. Health Care Manage Rev 2012; 37: 257-266.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Daniel O’Connor, Roderick McKay and Gerard Byrne, executive members of the Faculty of Psychiatry of Old Age, Royal Australian New Zealand College of Psychiatrists (RANZCP) for discussing with us the issues covered in this article.
We are both executive members of the Faculty of Psychiatry of Old Age, RANZCP. The views expressed in this article are our own and not those of the RANZCP. Stephen Macfarlane has received speaker’s honoraria from Eli Lilly, Janssen-Cilag, Pfizer and Lundbeck, and a Lundbeck Fellowship to attend a series of seminars on dementia held at the Lundbeck Institute in Skodsborg, Denmark, in 2009.